Patient-Enhanced Drug Discovery and Development Date Published: Aug 17, 2020 Article This PharmaVoice article argues that patients should be viewed as partners in drug development. While big pharma companies are incorporating the patient experience more in R&D, it’s not in a consistent manner. From informed consent forms and recruitment materials to study design, aspects of a trial can easily be adapted to include patient insights. Find out the mutual benefits to forming relationships with patients and how pharma companies are starting to applying this approach to their clinical trial studies. Contributing industry members include Signant Heath’s Bill Byrom, AstraZeneca’s Helena Chung, and Antidot’s Lindsey Wahlstrom-Edwards. Read More Share: LinkedInTweet Recommended Resources Article Optimal COA Measurement Strategy in Modern Oncology Trials The inclusion of patient-reported outcomes (PRO) data in oncology medication labeling in the U.S. has been comparatively limited. Recent FDA... Read Now Article Innovations in Clinical Neuroscience: Articles on Pediatric and Orphan Disease Clinical Research Dr. Joan Busner, Signant’s Clinical Vice President and in-house expert on pediatric and orphan disease clinical trials, recently co-authored three... Download Now Article Cariprazine Found to be Effective Adjunctive Treatment for Major Depressive Disorder Treating major depressive disorder can be challenging since many patients do not respond to initial antidepressant treatment, leading to continued... Read the Article